Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Ratio (2016 - 2026)

Akebia Therapeutics has reported Equity Ratio over the past 11 years, most recently at 0.09 for Q4 2025.

  • Quarterly Equity Ratio rose 138.85% to 0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.09 through Dec 2025, up 138.85% year-over-year, with the annual reading at 0.09 for FY2025, 138.85% up from the prior year.
  • Equity Ratio was 0.09 for Q4 2025 at Akebia Therapeutics, down from 0.11 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.34 in Q1 2021 and troughed at 0.24 in Q3 2024.
  • The 5-year median for Equity Ratio is 0.03 (2022), against an average of 0.02.
  • Year-over-year, Equity Ratio tumbled 1002.31% in 2023 and then skyrocketed 165.55% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.14 in 2021, then plummeted by 89.49% to 0.01 in 2022, then crashed by 961.44% to 0.13 in 2023, then plummeted by 76.15% to 0.22 in 2024, then skyrocketed by 138.85% to 0.09 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Equity Ratio are 0.09 (Q4 2025), 0.11 (Q3 2025), and 0.08 (Q2 2025).